View More Recent Stories

Dec 11, 2024 04:07PM Corcept Therapeutics (CORT) Announces Results From Phase 2 Study of Dazucorilant

Oct 31, 2024 07:58AM H.C. Wainwright Reiterates Buy Rating on Corcept Therapeutics (CORT)

Oct 30, 2024 04:20PM Corcept Therapeutics (CORT) Tops Q3 EPS by 13c, provides guidance

Oct 30, 2024 04:06PM Corcept Therapeutics (CORT) Reports Q3, Announces Positive Results From Phase 3 GRADIENT Trial

Oct 21, 2024 06:16AM Truist Securities Reiterates Buy Rating on Corcept Therapeutics (CORT)

Oct 20, 2024 10:00AM 4 biotech stocks to own to benefit from key Q4 catalysts

Oct 18, 2024 06:40AM Corcept Therapeutics (CORT) PT Raised to $80 at H.C. Wainwright

Sep 30, 2024 06:08AM Corcept Therapeutics (CORT) PT Raised to $76 at Truist Securities

Sep 25, 2024 07:06AM Canaccord Genuity Reiterates Buy Rating on Corcept Therapeutics (CORT)

Aug 15, 2024 06:50AM Canaccord Genuity Reiterates Buy Rating on Corcept Therapeutics (CORT)

Jul 31, 2024 06:27AM Corcept Therapeutics (CORT) PT Raised to $78 at Canaccord Genuity

Jul 30, 2024 07:10AM Corcept Therapeutics (CORT) PT Raised to $38 at Piper Sandler

Jul 30, 2024 06:44AM Corcept Therapeutics (CORT) PT Raised to $45 at H.C. Wainwright

Jul 29, 2024 04:18PM Corcept Therapeutics (CORT) Tops Q2 EPS by 9c

Jul 17, 2024 08:34AM Piper Sandler Reiterates Overweight Rating on Corcept Therapeutics (CORT)

Jul 1, 2024 07:14AM Piper Sandler Reiterates Overweight Rating on Corcept Therapeutics (CORT)

Jun 12, 2024 07:45AM Canaccord Genuity Reiterates Buy Rating on Corcept Therapeutics (CORT)

Jun 10, 2024 06:49AM Piper Sandler Reiterates Overweight Rating on Corcept Therapeutics (CORT)

View More Recent Stories